Increased Revenue Guidance
Sight Sciences raised its full-year 2025 revenue guidance to $76 million to $78 million, up from the previous guidance of $72 million to $76 million.
Surgical Glaucoma Revenue Growth
The Surgical Glaucoma segment reported a revenue of $19.7 million in Q3 2025, reflecting a 6% increase compared to the same period in the previous year.
Successful Payer Coverage for TearCare
The company achieved pricing schedules for TearCare with First Coast Service Options and Novitas Solutions, covering 10.4 million Medicare lives and setting a payment rate of approximately $1,142.
Record High for Ordering Accounts
Ordering accounts reached a record high for the second consecutive quarter, with a 2% sequential increase and an 8% increase compared to the previous year.
Management Restructuring
Promotion of Ali Bauerlein to Chief Operating Officer and Jim Rodberg to Chief Financial Officer, both having significant experience within the company.